AEZ. AEterna Zentaris Inc.

Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

CHARLESTON, S.C., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) will announce its second quarter 2018 financial and operating results after market close on Thursday, August 9, 2018. The Company will host a conference call to discuss these results on Friday, August 10, 2018 at 8:30 a.m. Eastern Time.

Participants may access the conference call by telephone using the following numbers:

  • Toll-Free: 877-407-8029, Confirmation #13681858
  • Toll: 201-689-8029, Confirmation #13681858

A replay will also be available on the Company’s website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency.  Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit .

Contact:

Aeterna Zentaris Inc.

James Clavijo

Chief Financial Officer



843-900-3201

EN
02/08/2018

Underlying

AEZ.AEterna Zentaris Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AEterna Zentaris Inc.

 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate completing the Transaction in the sec...

March 28, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial R...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentar...

March 27, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Spec...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the following voting result...

March 12, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentari...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.”ISS states in its Ceapro FOR recommendation that “The arrangement is the result of arm's length negotiations between the partie...

February 26, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Ci...

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at Shareholders with questions or who require assistance voting their shares should contact Kingsdale Advisors at 1-866-581-1513 (North American Toll Free) or 416-623-2513 (outside North America – text and call enabled) or TORONTO, Feb. ...

February 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch